Fem-Dophilus® contains two patented and clinically documented probiotic strains, Lactobacillus rhamnosus, GR-1® and Lactobacillus reuteri, RC-14®, discovered and developed by Dr. Gregor Reid and Dr. Andrew Bruce at Urex Biotech. Over 25 years of research supports the oral use of GR-1® and RC-14® to colonize and promote healthy vaginal and urinary tract health. A special manufacturing process protects the probiotic strains in Fem-Dophilus® from stomach acid and enhances probiotic bacterial survival to the lower intestine.

GR-1®/RC-14® and VAGINAL FLORA (also called microbiota)

In one of the randomized clinical trials, 75% of women in the GR-1®/RC-14® probiotic group experienced significant improvement in vaginal flora composition, while only 34% of women in the placebo (non-probiotic) group experienced similar improvement.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.